WARNING: THE EDGAR SYSTEM ENCOUNTERED ERROR(S) WHILE PROCESSING THIS SCHEDULE.

  


                                                    

                                      FINANCIAL DATA SCHEDULE


                                   ARONEX PHARMACEUTICALS, INC.     Exhibit 27.1
<ARTICLE>                                                                      5
<LEGEND>                THIS SCHEDULE  CONTAINS  SUMMARY  FINANCIAL  INFORMATION
                    EXTRACTED   FROM  THE   FINANCIAL   STATEMENTS   OF   ARONEX
                    PHARMACEUTICALS,  INC. SET FORTH IN THE COMPANY'S  FORM 10-Q
                    FOR THE SIX MONTHS  ENDED JUNE 30, 1998 AND IS  QUALIFIED IN
                    ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER>                                                                   1
       
                                                                          
<PERIOD-TYPE>                                                              6-MOS
<FISCAL-YEAR-END>                                                    DEC-31-1998
<PERIOD-END>                                                         JUN-30-1998
<CASH>                                                                 6,265,000
<SECURITIES>                                                          14,966,000
<RECEIVABLES>                                                                  0
<ALLOWANCES>                                                                   0
<INVENTORY>                                                                    0
<CURRENT-ASSETS>                                                      20,496,000
<PP&E>                                                                 4,780,000
<DEPRECIATION>                                                         2,619,000
<TOTAL-ASSETS>                                                        24,166,000
<CURRENT-LIABILITIES>                                                  5,842,000
<BONDS>                                                                        0
<COMMON>                                                                  15,000
<PREFERRED-MANDATORY>                                                          0
<PREFERRED>                                                                    0
<OTHER-SE>                                                            17,212,000
<TOTAL-LIABILITY-AND-EQUITY>                                          24,166,000
<SALES>                                                                        0
<TOTAL-REVENUES>                                                         941,000
<CGS>                                                                          0
<TOTAL-COSTS>                                                                  0 
<OTHER-EXPENSES>                                                      11,414,000
<LOSS-PROVISION>                                                               0
<INTEREST-EXPENSE>                                                        14,000
<INCOME-PRETAX>                                                     (10,487,000)
<INCOME-TAX>                                                                   0
<INCOME-CONTINUING>                                                 (10,487,000)
<DISCONTINUED>                                                                 0
<EXTRAORDINARY>                                                                0
<CHANGES>                                                                      0
<NET-INCOME>                                                        (10,487,000)
<EPS-PRIMARY>                                                              (.68)
<EPS-DILUTED>                                                              (.68)